News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
700,247 Results
Type
Article (40301)
Company Profile (254)
Press Release (659692)
Multimedia
Podcasts (51)
Webinars (12)
Section
Business (204489)
Career Advice (2019)
Deals (35449)
Drug Delivery (95)
Drug Development (81178)
Employer Resources (172)
FDA (16207)
Job Trends (14915)
News (345694)
Policy (32570)
Tag
Academia (2582)
Accelerated approval (5)
Adcomms (21)
Allergies (85)
Alliances (49529)
ALS (89)
Alzheimer's disease (1393)
Antibody-drug conjugate (ADC) (124)
Approvals (16209)
Artificial intelligence (254)
Autoimmune disease (21)
Automation (16)
Bankruptcy (360)
Best Places to Work (11685)
BIOSECURE Act (19)
Biosimilars (105)
Biotechnology (181)
Bladder cancer (77)
Brain cancer (27)
Breast cancer (278)
Cancer (2250)
Cardiovascular disease (173)
Career advice (1684)
Career pathing (30)
CAR-T (151)
Cell therapy (423)
Cervical cancer (19)
Clinical research (66061)
Collaboration (835)
Compensation (524)
Complete response letters (20)
COVID-19 (2590)
CRISPR (40)
C-suite (243)
Cystic fibrosis (100)
Data (2196)
Decentralized trials (2)
Denatured (18)
Depression (48)
Diabetes (270)
Diagnostics (6369)
Digital health (18)
Diversity (8)
Diversity, equity & inclusion (44)
Drug discovery (120)
Drug pricing (98)
Drug shortages (25)
Duchenne muscular dystrophy (93)
Earnings (86642)
Editorial (37)
Employer branding (21)
Employer resources (146)
Events (112607)
Executive appointments (724)
FDA (17456)
Fibrodysplasia Ossificans Progressiva (1)
Friedreich's ataxia (4)
Frontotemporal dementia (7)
Funding (751)
Gene editing (104)
Generative AI (19)
Gene therapy (301)
GLP-1 (711)
Government (4421)
Grass and pollen (4)
Guidances (59)
Healthcare (18844)
Huntington's disease (23)
IgA nephropathy (27)
Immunology and inflammation (116)
Indications (29)
Infectious disease (2732)
Inflammatory bowel disease (136)
Inflation Reduction Act (8)
Influenza (51)
Intellectual property (97)
Interviews (314)
IPO (16519)
IRA (40)
Job creations (3646)
Job search strategy (1430)
Kidney cancer (10)
Labor market (38)
Layoffs (468)
Leadership (17)
Legal (7919)
Liver cancer (75)
Lung cancer (320)
Lymphoma (153)
Machine learning (7)
Management (58)
Manufacturing (304)
MASH (66)
Medical device (13397)
Medtech (13402)
Mergers & acquisitions (19475)
Metabolic disorders (683)
Multiple sclerosis (80)
NASH (16)
Neurodegenerative disease (94)
Neuropsychiatric disorders (30)
Neuroscience (1941)
NextGen: Class of 2025 (6536)
Non-profit (4490)
Now hiring (39)
Obesity (363)
Opinion (205)
Ovarian cancer (75)
Pain (86)
Pancreatic cancer (83)
Parkinson's disease (152)
Partnered (21)
Patents (234)
Patient recruitment (110)
Peanut (46)
People (57416)
Pharmaceutical (64)
Pharmacy benefit managers (18)
Phase I (20578)
Phase II (29089)
Phase III (21669)
Pipeline (1185)
Policy (139)
Postmarket research (2567)
Preclinical (8770)
Press Release (64)
Prostate cancer (106)
Psychedelics (30)
Radiopharmaceuticals (246)
Rare diseases (379)
Real estate (5924)
Recruiting (65)
Regulatory (22292)
Reports (46)
Research institute (2340)
Resumes & cover letters (350)
Rett syndrome (5)
RNA editing (5)
RSV (42)
Schizophrenia (72)
Series A (131)
Series B (86)
Service/supplier (11)
Sickle cell disease (52)
Special edition (16)
Spinal muscular atrophy (147)
Sponsored (29)
Startups (3591)
State (2)
Stomach cancer (13)
Supply chain (68)
Tariffs (39)
The Weekly (31)
Vaccines (685)
Venture capitalists (41)
Weight loss (234)
Women's health (35)
Worklife (16)
Date
Today (164)
Last 7 days (851)
Last 30 days (2610)
Last 365 days (32878)
2025 (10608)
2024 (35303)
2023 (40161)
2022 (51251)
2021 (55793)
2020 (54154)
2019 (46602)
2018 (35088)
2017 (32173)
2016 (31586)
2015 (37658)
2014 (31432)
2013 (26463)
2012 (28658)
2011 (29324)
2010 (27378)
Location
Africa (719)
Alabama (53)
Alaska (7)
Arizona (231)
Arkansas (13)
Asia (37943)
Australia (6215)
California (6104)
Canada (2009)
China (522)
Colorado (265)
Connecticut (272)
Delaware (146)
Europe (81620)
Florida (908)
Georgia (205)
Idaho (57)
Illinois (541)
India (25)
Indiana (307)
Iowa (11)
Japan (161)
Kansas (104)
Kentucky (23)
Louisiana (10)
Maine (62)
Maryland (886)
Massachusetts (4566)
Michigan (219)
Minnesota (391)
Mississippi (2)
Missouri (81)
Montana (27)
Nebraska (25)
Nevada (63)
New Hampshire (63)
New Jersey (1721)
New Mexico (28)
New York (1739)
North Carolina (965)
North Dakota (8)
Northern California (2667)
Ohio (203)
Oklahoma (14)
Oregon (34)
Pennsylvania (1373)
Puerto Rico (12)
Rhode Island (33)
South America (1099)
South Carolina (22)
South Dakota (1)
Southern California (2288)
Tennessee (102)
Texas (905)
United States (23053)
Utah (180)
Virginia (144)
Washington D.C. (63)
Washington State (550)
West Virginia (3)
Wisconsin (53)
700,247 Results for "minerva neurosciences inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Minerva Neurosciences Reports Fourth Quarter and Fiscal Year 2024 Financial Results and Business Updates
February 26, 2025
·
7 min read
Business
Minerva Neurosciences Reports First Quarter 2024 Financial Results and Business Updates
Minerva Neurosciences, Inc. today reported business updates and financial results for the first quarter of 2024 ending March 31, 2024.
May 1, 2024
·
6 min read
Press Releases
Minerva Neurosciences Reports Third Quarter 2024 Financial Results and Business Updates
November 5, 2024
·
6 min read
Business
Minerva Neurosciences Reports Fourth Quarter and Fiscal Year 2023 Financial Results and Business Updates
Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system disorders, today reported business updates and financial results for the fourth quarter and year ended December 31, 2023.
February 22, 2024
·
6 min read
Business
Minerva Neurosciences Reports 2023 Third Quarter Financial Results and Business Updates
Minerva Neurosciences, Inc. reported business updates and financial results for the third quarter ended September 30, 2023.
November 7, 2023
·
6 min read
Genetown
Minerva Neurosciences Receives Complete Response Letter from FDA for New Drug Application for Roluperidone for the Treatment of Negative Symptoms in Patients with Schizophrenia
Minerva Neurosciences, Inc. announced today that the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) to the Company’s New Drug Application (NDA) for roluperidone for the treatment of negative symptoms in patients with schizophrenia.
February 27, 2024
·
6 min read
Drug Development
Minerva’s Schizophrenia Candidate Rejected by FDA in Complete Response Letter
The FDA has rejected Minerva Neurosciences’ treatment for negative symptoms in schizophrenia, noting a lack of data and other factors that led to the Complete Response Letter.
February 27, 2024
·
2 min read
·
Tyler Patchen
Press Releases
Minerva Neurosciences Reports Second Quarter 2024 Financial Results and Business Updates
August 6, 2024
·
6 min read
Business
Minerva Neurosciences Reports 2023 Second Quarter Financial Results and Business Updates
Minerva Neurosciences, Inc. today reported business updates and financial results for the second quarter ended June 30, 2023.
August 1, 2023
·
7 min read
Business
Minerva Neurosciences Reports 2023 First Quarter Financial Results and Business Updates
Minerva Neurosciences, Inc. reported business updates and financial results for the first quarter ended March 31, 2023.
May 15, 2023
·
7 min read
1 of 70,025
Next
